ReviewCritical reviews in oncogenesis2013
Iron in multiple myeloma.
Review in Critical reviews in oncogenesis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- The Effect of a Six-Week Nordic Walking Training Cycle on Oxidative Damage of Macromolecules and Iron Metabolism in Older Patients with Multiple Myeloma in Remission-Randomized Clinical Trial.International journal of molecular sciences · 2023Trial
- Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma.Blood · 2026Article
- IgM Myeloma: A Comprehensive Overview and Practical Approach to Chemotherapeutic Management.World journal of oncology · 2025Review
- Splenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma.European radiology · 2025Article
- Article
- Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders.European journal of haematology · 2024Article
- Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma.Oncogene · 2024Article
- Comparison of trace elements in peripheral blood and bone marrow of newly diagnosed multiple myeloma patients.Clinical and experimental medicine · 2024Article
- The Relationship between Changes in Serum Element Concentrations and Pathological Condition and Disease Status in Japanese Multiple Myeloma Patients: A Pilot Study and Literature Review.Asian Pacific journal of cancer prevention : APJCP · 2023Review
- The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment.Medicina (Kaunas, Lithuania) · 2022Article
- Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents.Frontiers in immunology · 2021Review
- New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia.Journal of clinical medicine · 2019Review
- Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- OWL-NETS: Transforming OWL Representations for Improved Network Inference.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2018Article
- Expression of Hepcidin and Neogenin in Colorectal Cancer.Open medicine (Warsaw, Poland) · 2017Article
- FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells.Oncotarget · 2015Article
- Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation.Cancer research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Multiple myeloma is a non-curable B-cell malignancy in which iron metabolism plays an important role. Patients with this disorder almost universally suffer from clinically significant anemia, which is often symptomatic, and which is due to impaired iron utilization. Recent studies have indicated that the proximal cause of dysregulated iron metabolism and anemia in these patients is cytokine-induced upregulation of hepcidin expression. Malignant myeloma cells are dependent on an increased influx of iron, and therapeutic efforts are being made to target this requirement. The studies detailing the characteristics and biochemical abnormalities in iron metabolism causing anemia and the initial attempts to target iron therapeutically are described in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.